Recurrent Glioblastoma

The reemergence of glioblastoma after a period of remission.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
PURPOSE To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma. PATIENTS AND METHODS Patients… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Bevacizumab has recently been approved by the US Food and Drug Administration for recurrent glioblastoma (GBM… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Early imaging or blood biomarkers of tumor response are desperately needed to customize antiangiogenic therapy for cancer… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE Bevacizumab has been shown to be effective in the treatment of recurrent glioblastoma in combination with chemotherapy… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND There is much discussion in the cancer drug development community about how to incorporate molecular tools into early… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Cilengitide, an inhibitor of alphavbeta3 and alphavbeta5 integrin receptors, demonstrated minimal toxicity and durable… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
TO THE EDITOR: I congratulate Vredenburgh and colleagues for their article further supporting the role of bevacizumab and… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Using MRI techniques, we show here that normalization of tumor vessels in recurrent glioblastoma patients by daily administration… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal… (More)
Is this relevant?